FindTrial
Sign In

Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion.

DRUG3 trials

Sponsors

F. Hoffmann-La Roche AG, Assistance Publique Hopitaux De Paris, Institut De Recherches Internationales Servier IRIS

Conditions

"Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Chronic Lymphocytic Leukemia (CLL)Myelodysplastic Syndrome (MDS)/AMLPatients hospitalised in intensive careadultsdiagnosed with sepsis less than 48 hours agonegative G6PD deficiencyor Chronic Myelomonocytic Leukemia (CMML)"

Phase 1

Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination with Venetoclax in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)
CompletedCTIS2024-514356-33-00
Institut De Recherches Internationales Servier IRISMyelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)", "Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Start: 2025-02-11End: 2025-10-13Target: 54Updated: 2025-08-04

Phase 3

A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients with CLL and Coexisting Medical Conditions
CompletedCTIS2023-504034-22-00
F. Hoffmann-La Roche AGChronic Lymphocytic Leukemia (CLL)
Start: 2014-12-18End: 2025-08-06Target: 267Updated: 2025-06-27
RASBU-SEPSIS Study: Effects of rasburicase on renal function during sepsis – a randomized, placebo-controlled, double-blind trial
Not yet recruitingCTIS2023-508071-36-00
Assistance Publique Hopitaux De Parisadults, diagnosed with sepsis less than 48 hours ago, negative G6PD deficiency +2
Target: 240Updated: 2025-11-24